97 related articles for article (PubMed ID: 7951272)
21. The advantages and disadvantages of adaptive designs for clinical trials.
Bauer P; Brannath W
Drug Discov Today; 2004 Apr; 9(8):351-7. PubMed ID: 15081962
[TBL] [Abstract][Full Text] [Related]
22. [Group allocation by random procedure in field trial (Latin square in working out the list for random allocation) (author's transl)].
Bencić Z
Lijec Vjesn; 1981 Oct; 103(10):425-30. PubMed ID: 7341896
[No Abstract] [Full Text] [Related]
23. Test for the consistency of noninferiority from multiple clinical trials.
Yan X; Wang MC; Su X
J Biopharm Stat; 2007; 17(2):265-78. PubMed ID: 17365223
[TBL] [Abstract][Full Text] [Related]
24. A two-stage design for choosing among several experimental treatments and a control in clinical trials.
Thall PF; Simon R; Ellenberg SS
Biometrics; 1989 Jun; 45(2):537-47. PubMed ID: 2765637
[TBL] [Abstract][Full Text] [Related]
25. [The importance of equivalence trials in showing the usefulness of treatments].
Hermens ML; van Hout HP; Terluin B; Adèr HJ; de Haan M
Ned Tijdschr Geneeskd; 2003 Nov; 147(44):2162-6. PubMed ID: 14626832
[TBL] [Abstract][Full Text] [Related]
26. [Assessing adverse reactions in clinical trials].
Harnisch S; Schade-Brittinger C; Rief W
Dtsch Med Wochenschr; 2012 Jul; 137(27):1421-5. PubMed ID: 22736184
[TBL] [Abstract][Full Text] [Related]
27. Interim analyses in randomized clinical trials: ramifications and guidelines for practitioners.
Geller NL; Pocock SJ
Biometrics; 1987 Mar; 43(1):213-23. PubMed ID: 3567306
[TBL] [Abstract][Full Text] [Related]
28. A group sequential type design for three-arm non-inferiority trials with binary endpoints.
Li G; Gao S
Biom J; 2010 Aug; 52(4):504-18. PubMed ID: 20645389
[TBL] [Abstract][Full Text] [Related]
29. Application of restricted sequential design in a clinical protocol.
Thompson EI
Cancer Treat Rep; 1980; 64(2-3):399-403. PubMed ID: 7407776
[TBL] [Abstract][Full Text] [Related]
30. Evaluation and recommendations on adaptive dose-ranging trials: highlights from the PhRMA Adaptive Dose-Ranging Studies Working Group.
Pinheiro J
J Clin Pharmacol; 2010 Sep; 50(9 Suppl):47S-49S. PubMed ID: 20881216
[No Abstract] [Full Text] [Related]
31. Clinical trials:randomization before consent.
Armstrong PW; Watts DG
Biomedicine; 1981 Sep; 34(2):65-6. PubMed ID: 7284544
[TBL] [Abstract][Full Text] [Related]
32. Drug therapy: safety, effectiveness, and economics.
Brandys J
Przegl Lek; 2001; 58(4):226-8. PubMed ID: 11450340
[TBL] [Abstract][Full Text] [Related]
33. Noninferiority testing beyond simple two-sample comparison.
Tsong Y; Chen WJ
J Biopharm Stat; 2007; 17(2):289-308. PubMed ID: 17365225
[TBL] [Abstract][Full Text] [Related]
34. Placebo in clinical drug trials--a multidisciplinary review.
Haegerstam G; Huitfeldt B; Nilsson BS; Sjövall J; Syvälahti E; Wahlén A
Methods Find Exp Clin Pharmacol; 1982; 4(4):261-78. PubMed ID: 6750286
[TBL] [Abstract][Full Text] [Related]
35. Using disease progression models as a tool to detect drug effect.
Mould DR; Denman NG; Duffull S
Clin Pharmacol Ther; 2007 Jul; 82(1):81-6. PubMed ID: 17507925
[TBL] [Abstract][Full Text] [Related]
36. Hypothesis testing vs. statistical estimation procedures in caries clinical trials.
Fertig JW
J Dent Res; 1984 May; 63 Spec No():808-13. PubMed ID: 6586785
[No Abstract] [Full Text] [Related]
37. Monitoring pairwise comparisons in multi-armed clinical trials.
Follmann DA; Proschan MA; Geller NL
Biometrics; 1994 Jun; 50(2):325-36. PubMed ID: 8068834
[TBL] [Abstract][Full Text] [Related]
38. An adaptive group sequential design for phase II/III clinical trials that select a single treatment from several.
Kelly PJ; Stallard N; Todd S
J Biopharm Stat; 2005; 15(4):641-58. PubMed ID: 16022169
[TBL] [Abstract][Full Text] [Related]
39. Sample size determination in step-up testing procedures for multiple comparisons with a control.
Kwong KS; Cheung SH; Wen MJ
Stat Med; 2010 Nov; 29(26):2743-56. PubMed ID: 20799258
[TBL] [Abstract][Full Text] [Related]
40. A safety monitoring procedure for a clinical drug development program, with application to the assessment of a novel COX-2 inhibitor.
Bolland K; Whitehead J; Oldham M
J Biopharm Stat; 2008; 18(4):737-49. PubMed ID: 18607805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
